Impacts of IL-27 and IL-32 in the pathogenesis and outcome of COVID-19 associated mucormycosis.

Zamani, Batool; Momen-Heravi, Mansooreh; Erami, Mahzad; Motedayyen, Hossein; ArefNezhad, Reza

Zamani, Batool; Momen-Heravi, Mansooreh; Erami, Mahzad; Motedayyen, Hossein; ArefNezhad, Reza.

Afiliación

Zamani B; Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.
Momen-Heravi M; Department of Infectious Diseases, School of Medicine, Infectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.
Erami M; Kashan Shahid Beheshti Hospital, Kashan University of Medical Sciences, Kashan, Iran.
Motedayyen H; Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.
ArefNezhad R; Coenzyme R Research Institute, Tehran, Iran.

J Immunoassay Immunochem ; 44(3): 242-255, 2023 May 04.

Article en En | MEDLINE | ID: mdl-36602425

Asunto(s)

COVID-19; Interleucina-27; Mucormicosis; Humanos; Interleucinas; Ensayo de Inmunoadsorción Enzimática

Palabras clave

COVID-19; IL-27; IL-32; disease outcome; mucormycosis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Interleucina-27 / COVID-19 / Mucormicosis Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Immunoassay Immunochem Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google